Premium Essay

Big Pharma

In: Social Issues

Submitted By edge8220
Words 276
Pages 2
The effect of big pharma on healthcare

EN 1320

26 May 2013

The effect of big pharma on healthcare
Big pharmacy has always been a hot button issue, for as long as I can remember. It is proven that the large drug companies are using unethical practices to help boost sales. These practices in turn cost the patient more at the counter in the pharmacy. This also leads to shady practices by physicians.
Fortune magazine reported that in 2008, the pharmaceutical industry continued to be in the top three most profitable industries in the United States for the past two decades. Studies show that marketing strategies used by pharmaceutical representatives such as education, samples, office support, and patient resources can increase brand recognition and influence prescribing. This leads to patients being influenced to spend more money on the brand name drugs, rather than the cheaper generic versions that work exactly the same.

References
Insert References Here. Place the cursor at the beginning of this line, and then, on the CiteWrite menu, click Format, Write Bibliography.
For more help with your references, click Start, Programs, Dr Paper, Dr Paper Help, and go through the instructions under Using CiteWrite for your References. If you just have one or two references, you might want to just type them by hand, following these examples:
Hall, K. G. (2005, August 29). Web page title. Website title. Retrieved September 25, 2005, from http://www.kansas.com/mld/kansas/12506343.htm.
Smith, A. (1999). Article title. Journal name, 8, 243.
Wilson, J. B. (1999). Book title. Place of publication: Publisher.
Make sure you delete this text before you turn in your…...

Similar Documents

Free Essay

Pharma

...Respected Sir/Madam, I xxxx completed Bachelors in xyz College of xyz affiliated to University, Mumbai with 50% Following this, I was involved in research and has been working as an Analyst for Plant pharmaceuticals in Quality Control Department of Alapati Pharma company. I was Kindled with an ambition of higher education that would give a desired push to my career. With a strong will to pursue my further studies in Canada, I prepared for the IELTS examination and scored 6.5 bands. I am prepared to further deepen and refine my expertise through Biotechnology Course which has led me to take admission in one of the top Colleges, Centennial College, Canada. I was brought up in a well educated family and this helped me to maintain a consistent and excellent academic record; I secured Distinction marks in SSC and Intermediate. During my Bachelors, I submitted many research papers in worldwide and India wide seminars like IPC, IPA, National seminars where 12 of my Research papers were published in Medical and Pharmacy Journals. I was also awarded a "Gold medal" for a Seminar conducted by Indian Pharmaceutical Congress which provided me a wonderful platform to meet the top heads of Pharmaceutical Industry in the country. I Started my career as an Asst. Manufacturing Chemist in Triomed Formulations India(Pvt) Ltd as soon as i was graduated. Then i opted for a Subject Knowledge Enhancement Course......

Words: 741 - Pages: 3

Free Essay

Pharma

...amount of capital available to buy stocks. Therefore the prices of stocks increased rapidly. Even before the companies made real profits the prices of their stocks were very high. Suddenly the confidence fell and many companies went bankrupt dragging down investors. (17) Asian Crisis 1997-2000 The Asian Crisis is the first crisis in which more thorough investigations of the consequences on health were performed. The Asian Crisis started in Thailand. After several years of economic prosperity Thailand developed one of the highest current account deficiencies among developing countries (8% of GDP in 1995 and 1996).(7) A decline in demand for Thai export products led to the collapse of the Thai baht. The central bank‘s reserves were not big enough to maintain the value of the Thai baht to the USA dollar. A lack of confidence in the economies combined with the decline in currencies lead to a capital outflow, bankruptcy and unemployment. The crisis spread from Thailand to the other countries in Asia. Indonesia, Thailand and South Korea were the countries most affected in South-East Asia, followed by Malaysia, Hong Kong, Philippines and Laos. Taiwan, India, Singapore, Brunei and China were the countries which were affected least.(18) Thailand, South Korea and Indonesia received support from the International Monetary Fund (IMF) to stabilize their currency. (19) IMF demanded these countries to restructure their banking sector and required the countries to keep their interest......

Words: 25253 - Pages: 102

Premium Essay

Pharma

........................ 35 MERGER AND ACQUISITION (M&A) ACTIVITIES .................................. 36 MARKET OUTLOOK AND RECOMMENDATIONS ...................................... 38 COUNTRY PROFILES ......................................................................................... 41 COMPANY PROFILES ........................................................................................ 48 GCC Pharmaceutical Sector | March 31, 2013 Page | 3 “The pharma sector in Qatar is poised for growth over the next few years in line with the growth trend in GCC, which is the wider market segment. A major driver to this will be the projected growth in the economy. On the regulatory side, the recent legislation proposed by the Supreme Health Council towards deregulation of pharmaceutical imports to encourage free market competition is a step in the right direction. The industry is also looking forward to the proposed national health insurance program, as this is perceived to be a catalyst to growth of the pharma industry in Qatar.” Sheikh Faisal Bin Qassim Al Thani Chairman Aamal Company (Ebn Sina Pharmacy) “The GCC pharmaceutical sector has been growing steadily along with the general uptrend within the region. The pharmaceutical sector is highly regulated in nature and hence comes with its own limitations with regards to registration and entry into new markets. However, the recent trend of increased use of generics and the growth in medical insurance penetration will...

Words: 27542 - Pages: 111

Premium Essay

Pharma Industry

... | |EUR / USD |1.2438 | |GBP / USD |1.8333 | |USD / JPY |108.1508 | |USD / CHF |1.2426 | |Source: calculated using Federal Reserve daily data | Industry Trends Here we examine structural changes causing significant transformations, major factors leading to strong future sales growth, and point out the industry’s strong reliance on research and development. Structural changes The pharmaceutical industry is currently undergoing a period of very significant transformation. The majority of “Big Pharma” companies generate high returns, thus providing them with excess cash for further rapid growth – whether organic, or through mergers and acquisitions. Although size of the company on its own does not guarantee success, it gives a significant advantage, especially in pharmaceutical industry. Besides economies of scale in manufacturing, clinical trials and marketing, bigger companies can allow investments in more research and development (R&D) projects that diversify their future drugs portfolio and make them much more stable in the long term. As the result, top-companies in the industry were active participants of mergers and acquisitions (M&A), new joint ventures and spin-offs of non-core businesses. The largest acquisitions in......

Words: 10094 - Pages: 41

Premium Essay

Indian Pharma

...Pharmaceutical and Medical Products Practice India Pharma 2020 Propelling access and acceptance, realising true potential The report is furnished to the recipient for information purposes only. Each recipient should conduct its own investigation and analysis of any such information contained in this report. No recipient is entitled to rely on the work of McKinsey & Company, Inc. contained in this report for any purpose. McKinsey & Company, Inc. makes no representations or warranties regarding the accuracy or completeness of such information and expressly disclaims any and all liabilities based on such information or on omissions therefrom. The recipient must not reproduce, disclose or distribute the information contained herein without the express prior written consent of McKinsey & Company, Inc. 12 Executive summary India Pharma 2020: Propelling access and acceptance, realising true potential 13 Global pharmaceutical markets are in the midst of major discontinuities. While growth in developed markets will slow down, emerging markets will become increasingly important in the coming decade. The Indian pharmaceuticals market, along with the markets of China, Brazil and Russia, will spearhead growth within these markets. The Indian pharmaceuticals market has characteristics that make it unique. First, branded generics dominate, making up for 70 to 80 per cent of the retail market. Second, local players have enjoyed a dominant position driven by......

Words: 9542 - Pages: 39

Premium Essay

Big Pharma

...Big Pharma: More Drugs Equals More Money Sarah Kutasi Georgian Court University Big Pharma pulls back the curtain on the multi-billion dollar pharmaceutical industry to expose the dangerous ways that illness is used, manipulated, and in some instances created, for capital gain. Focusing on the industry's marketing practices, media scholars and health professionals help viewers understand the ways in which direct-to-consumer (DTC) pharmaceutical advertising glamorizes and normalizes the use of prescription medication, and works in tandem with promotion to doctors. Combined, these industry practices shape how both patients and doctors understand and relate to disease and treatment. Being that I have worked in a pharmacy now for 5 years, this video has deeply impacted me and my way of thinking. Of course I see what I saw on this video every day, however I don’t think I realized how it doesn’t just affect Toms River, New Jersey, but rather the entire world. When patients come in with newspaper clippings on a certain drug, whether it be over the counter or prescription or when they simply say, “Oh I saw it on Dr. Oz” or “I saw it on a commercial” it often makes me wonder how gullible these people are. They need to realize the advertisements are made so that drug companies can make money and benefit from these pseudoscience medications. It makes me mad that hundreds of people come in throughout the day just looking for trouble when they are perfectly healthy. ...

Words: 669 - Pages: 3

Premium Essay

Pharma

...RESEARCH PROJECT ON “TRAINING AND DEVELOPMENT IN PHARMASUITICAL INDUSTRY WITH SPECIAL REFERENCE OF MANKIND PHARMA LTD” SUBMITTED IN PARTIAL FULFILLMENT OF DEGREE OF BACHELOR OF BUSINESS ADMINISTRATION SESSION (2011-2014) SUBMITTED TO: SUBMITTED BY: XYZ XYZ BBA III University Roll No. SUBMITTED TO ACKNOWLEGDEMENT “Gratitude is the hardest of emotions to express and one often does not find adequate words to convey what one feels and trying to express it” The present project file is an amalgamated of various thoughts and experiences .The successful completion of this project report would have not been possible without the help and guidance of number of people and specially to my project guide .I take this opportunity to thank all those who have directly and indirectly inspired, directed and helped me towards successful completion of this project report. I am also immensely indebted to my project guide, MS. Divya Vaid Lecturer, ICL, for his......

Words: 8569 - Pages: 35

Premium Essay

Pharma 2020

...www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision  # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and......

Words: 13197 - Pages: 53

Premium Essay

Plesico Pharma

...PLESICO PHARMA PRESENTED BYBalaji – PGP04.107 Ujjwal Bommala – PGP04.108 Ramya Gattamaneni – PGP04.111 Harsh Khambra – PGP04.112 Ganavi Madduri – PGP04.119 DISTRIBUTION CHANNEL – MEMBERS CFAs •Maintaining stock and forwarding to stockists •To avoid local state taxes. Margins around 1-2% •Paid yearly on the basis of the percentage of turnover •Simultaneously handles more than one company •Owns the title directly from the company •Margin of about 10% Stockists Distributors •Get the stock from stockists •Margin around 8% Retailer •Margins around 15 – 20 % depending on the type of drug •Pharmacists recommendation is based on profitability and relationship with representatives of various companies •State funded , central funded and large hospitals •Companies bid for tenders by funded institutions Institutional •7% of total sales in India Supply Big Retail •These form only 3% of the total sales •Manufactures don’t sell the products directly to these chains • They concentrate on margins • Less sensitive to brand equity Consuming • 25 – 30 % of the market and mostly in towns and rural areas Doctors • Not much penetration in India Internet Channel Product Differentiation • Not possible • The products are not unique and are mostly general • The company should strive to differentiate its products from the competition Cost leader • This is possible only with scales of economy • The company is a start up and has no advantage in...

Words: 306 - Pages: 2

Premium Essay

Big Bucks Big Harma

...Big Buck Big Pharma Case Study Big Bucks, Big Pharma pulls back the curtain on the multi-billion dollar pharmaceutical industry to expose the insidious ways that illness is used, manipulated and in some instances created, for capital gain. Using excerpts from drug company advertisements as well as news reports on the pharmaceutical industry, the documentary raised important questions and presents options for the consumer empowerment. The film examines how direct-to-consumer advertising of medications is a fairly recent innovation that has led to a sharp increase in the sales of prescription drugs. Americans are encouraged to “ask your doctor” for name brand drugs numerous times throughout the day. Doctor’s report that sometimes patients will request a medication they have seen advertised without even knowing what condition or symptoms it is meant to treat. Advertisements in fact provide very little information about prescription drugs. Instead, the drugs are emotionally branded by associating their names with images of happy people, living fulfilling lives, in beautiful settings. Other pharmaceutical advertisements present normal aspects of life as serious medical conditions, leading healthy people to believe that they need unnecessary, and potentially harmful, and prescriptions. Throughout the case study there were several different section: Branding Drugs, Swimming in Pills, Disease Mongering, No Free Lunch, and A Healthier Prescription. In the section Branding......

Words: 987 - Pages: 4

Premium Essay

Monopoly Big Pharma

...am sure will shake up the pharmaceutical industry, as for “Big Pharma” patents ensure a steady stream of exorbitant profits from new drugs for many years. For example, in the U.S., these patents could last 20 years from the time they are first filed, which results in drug companies being able to mark-up the cost of drugs as much as 569,000 percent higher than the cost of their actual raw materials. Working in the health industry (Health Insurance), I see how the unreasonably high drug costs leave many patients in a serious financial bind, as the types of drugs administered for serious conditions like cancer can cost upwards of $100,000 or more per year (for example, cancer patients end up taking on a burden of enormous debt). This type of situation is particularly problematic in developing countries, where the average individual makes far less than the average individual living in the US. To address this problem, China has taken advantage of World Trade Organization (WTO) guidelines that allow member countries to essentially bypass patent laws in special circumstances. But, can China take advantage of this situation and continue strengthening its legal framework, to become a generic producer of drugs not just for the domestic, but internationally? How would this affect the pharmaceutical industry worldwide? Should we start generating global standards in regards to this? Is it even morally correct for Big Pharma to hold these kinds of patents while there are people......

Words: 296 - Pages: 2

Free Essay

Valeant Pharma

...front of Congress for the severe price hikes of Nitropress and Isuprel * Potential loss of $300 million a year if congress forces Valeant to revert to original prices | Economical | * “Duty is to maximize profit of all products “(Rockoff & Silverman, 2015, p.3) * Company had a net debt of $30 billion, which fueled their serial acquisitions of patents (Dumortier, 2016, p. 5) * Increased pressure from shareholders to generate higher profits | Legal | * Numerous lawsuits * | S.W.O.T. Analysis Strengths | * Employs over 18,000 people worldwide * Known as a specialist in the fields of Neurology and Dermatology * Manufacturing locations around the world * Strong presence in North America markets (Valeant Pharma SWOT analysis, 2014, p. 1) | Weakness | * Net debt of $30 billion dollars * Poor R&D investment | Opportunities | * Increasing population with heart problems * Acquisitions of already established products | Threats | * Risk of “Generic” brands being produced due to high cost * Changes to U.S. healthcare regulations as a result of recent predatory pricing attempts | Focal Issue Valeant’s move to increase prices far beyond the reasonable grasp of patients is more than just the lust for profit; the bigger underlying issue that affects Valeant and indeed all pharmaceutical companies today is a question of ethics. Companies of this size are accountable to their shareholders first and foremost, as stated by......

Words: 1373 - Pages: 6

Premium Essay

Indian Pharma

...Pharmabiz :: Vision of India as pharma power house in 2020 Page 1 of 3 Search Here Search Home Editorial Services Interview Q&A Chronicle Specials ePharmail Archives Join Pharma | Login Home > Chronicle Specials News + Font Resize - Vision of India as pharma power house in 2020 Nandita Vijay, Bengaluru Thursday, December 15, 2011, 08:00 Hrs [IST] The Indian pharma industry has gained significant global presence in the last few years and has been competing with other major countries on equal terms. Its remarkable growth can be attributed to its ability to rapidly access and adopt new technologies and also to its success in evolving an effective mechanism to strengthen research and development. The industry's advanced manufacturing facilities have earned laurels from global regulatory authorities. As a result, the world today turns to the Indian pharma industry not only for high-quality and low-cost generic drugs, but also for in-licensing and out -licensing of drugs. The robust Indian pharma industry today produces a range of formulations, has the expertise for active pharmaceutical ingredients (APIs) and sees significant opportunities for value-creation. Hence, the theme of the 63rd edition of IPC, ‘Pharma Vision 2020: India: The Pharma Power house’, encapsulates the present stature of the Indian pharma industry. India, the pharma power house India ranks third in terms of manufacturing pharma products by volume and 14th in value......

Words: 2709 - Pages: 11

Free Essay

Pharma Analyse

...Analyse sectorielle Secteur de la « Santé / Pharma » 16 Avril 2009 Liminaires • Ce document a pour objet de dresser une analyse prospective de la filière « Santé / Pharma » – ses grands enjeux, ses forces en présence, ses mutations en cours – et de donner à voir des pistes de réflexions / de solutions, en particulier pour les laboratoires pharmaceutiques. • Il est organisé en trois principaux chapitres : • Premier chapitre : diagnostic flash du secteur restitué sous la forme d’une représentation de la • • filière et de ses mutations majeures. Deuxième chapitre : pistes de réflexion / de solution à engager à court ou moyen terme pour répondre aux changements (outre celles d’ores et déjà engagées par les leaders de la filière). Troisième chapitre : analyse détaillée de la filière. • Les abréviations / sigles techniques spécifiques au secteur sont explicités dans un glossaire chapitre 4. 2008 Copyright emoveo sarl. Tous droits réservés 2 Sommaire • 1- Représentation de la filière Santé / Pharma et de ses mutations majeures • Contexte et enjeux majeurs • Tendances de fond et ruptures • Chaîne de valeur et changements induits • Emergence de nouveaux acteurs • 2 - Pistes de réflexions et de solutions • 3 - Analyse détaillée de la filière • Analyse de marché et analyse de l’environnement • Extraits du rapport d’étude « Pharma 2020 : The vision – Which path will you take ? » • Zoom sur les outils CRM Pharma • Fiches d’identité des 15 premiers......

Words: 8260 - Pages: 34

Premium Essay

Pharma

...www.pwc.com/us/pharma Aspiring giants How small pharmas can drive to $1 billion — and beyond PwC’s PRTM Management Consulting Aspiring giants Executive summary Amid the volatile blend of opportunity and challenge that characterizes the global pharmaceutical industry, only a few small companies have managed to catapult their revenue over the $1 billion mark over the past two decades. Whether they chose to expand their therapeutic area focus and product portfolios, enter new geographies, or grow their core business, these aspiring giants pursued three distinct strategies to jump-start growth:  Leveraged core product and technology capabilities to launch differentiated products  Used mergers and acquisitions to gain new products and/or expand geographic presence  Built a strong, stable leadership team armed with a compelling vision and relentless drive The experiences of these winning companies offer lessons for today’s smaller pharma companies harboring the ambition to reach the $1 billion revenue mark. To achieve this milestone, these companies will need to excel in three areas: expanding a core area of expertise to deliver niche and valueadded products, adopting an acquisition and partnering mindset to expand product offerings and geographic presence, and attracting and retaining talented leaders. Focusing on these fronts can help position a pharma company to become a growth leader—rather than merely a follower—in......

Words: 4167 - Pages: 17